Drugs.com - Clinical Trials

Vivani Medical Achieves First Implant and Full Enrollment in the First-in-Human Clinical Trial of GLP-1 Implant NPM-115 in Obese or Overweight Adults

ALAMEDA, Calif.--(BUSINESS WIRE) March 13, 2025 -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today...

Mar 18, 2025 - 01:11
 0
Vivani Medical Achieves First Implant and Full Enrollment in the First-in-Human Clinical Trial of GLP-1 Implant NPM-115 in Obese or Overweight Adults
ALAMEDA, Calif.--(BUSINESS WIRE) March 13, 2025 -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today...
Read More

Tags:

Previous Article

Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Produ...

Next Article

Postdoc survey says, AI safety issue, Fauci defaced: Trump Tracker

Related Posts

Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus

Lipella Pharmaceuticals Granted FDA Approval for Expand...

Feb 9, 2025  0

BioRestorative Receives FDA Fast Track Designation for BRTX-100 Chronic Lumbar Disc Disease Program

BioRestorative Receives FDA Fast Track Designation for ...

Mar 1, 2025  0

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

Dyne Therapeutics Receives FDA Fast Track Designation f...

Feb 9, 2025  0